COMP <GO>
ARDT vs JNJ // ENTERPRISE SCALE & MARKET CAP
Ardent Health Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ARDT 1
— JNJ 5
▲ ENTERPRISE SCALE & MARKET CAP LEADER: JNJ
LAST: $12.03 (-2.19%) • MKT CAP: $1.73B
market-cap
$1.73B
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
market-cap
$662.49B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARDT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARDT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.50% | 25.50% | -15.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 34.70% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 2.10% | 28.50% | -26.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 6.00% | 6.00% | 0.00 | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.4 | 62.1 | -0.70 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 23.0x | -11.10 | ARDT | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.73B | $662.49B | -$660.76B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARDT REV | JNJ REV | ARDT GROSS % | JNJ GROSS % | ARDT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.32B | $94.19B | — | 67.9% | $470.5M | $19.70B |
| FY 2024 | $5.97B | $88.82B | — | 69.1% | $315.0M | $19.84B |
| FY 2023 | $5.41B | $85.16B | — | — | $221.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARDT // BETA —
JNJ // BETA 1.08